Supplementary in vivo experiments involving for example studies of expression patterns by Northern blotting or microarray testing are still essential to confirm that the sRNA candidate genes are indeed transcribed; such studies also provide information about temporal expression patterns, potential precursor forms and degradation products.
A description of all the pools required for microarray testing is presented in Table 3.
Interestingly, the antigen microarray test was very specific and had a very good positive predictive value.
Microarray testing was done in two batches but we found no evidence for a batch effect in our analyses.
There are over 2500 genes known in the donor region for the congenic strain, so as in previous examples, after QTL mapping, microarray testing was the single step that reduced the number of candidate genes the most.
To clarify the mechanism of action of methamidophos on the immune system in RSV-infected offspring mice, a DNA microarray test was performed on day 1 after infection (Table 3).
Lack of data on potential utility at this time, especially given limited resources, suggests that clinical genome-wide microarray testing is not yet justified for individuals with schizophrenia, except for the minority with syndromic and/or neurodevelopmental features such as mental retardation or multiple congenital anomalies.
When microarrays tests were applied, these authors found that highly phagocytic amoeba showed overexpression of at least 121 genes with respect to nonphagocytic amoeba; therefore, additional studies with E. dispar will be necessary to differentiate sub- and overexpressed genes in this species.
One reason for the paucity of microarray-based diagnostic tests is that DNA microarrays require considerable effort to achieve the level of technical refinement necessary for diagnostic practice.
The microarray testing phases are designed to evaluate the candidate external RNA controls on both one-color and two-color platforms using the same pools of transcripts.
